Tetrahedron Letters, Vol.27, No.5, pp 555-558, 1986 0040-4039/86 \$3.00 + .00 Printed in Great Britain ©1986 Pergamon Press Ltd.

STEREOCHEMICAL CONTROL OF THE GLYCOSYLATION REACTION VIA 3,5-Di-O-(p-TOLUOYL)-2-O-(p-TOLUOLSULFONYL)-8-D-METHYL RIBOFURANOSIDE¹

> Christos PAPAGEORGIOU and Christoph TAMM* Institut für Organische Chemie der Universität St. Johanns-Ring 19, CH-4056 Basel, Switzerland

ABSTRACT: Lewis acid catalyzed glycosylation of the 2'-tosyl ribofuranose derivative 5 leads exclusively to β -nucleosides in the uridine and adenosine series.

For our continuing studies on the chemical synthesis of oligoribonucleotides and the evaluation of their biological properties² it is necessary to have the monomeric nucleosidic units asymmetrically substituted. To synthesize these nucleosides, we have retained the method involving glycosylation of trimethylsilyl derivatives of nucleic bases with acylated sugar derivatives in the presence of Lewis acid³. The stereochemistry of the reaction is determined by the transient 1,2-acyloxonium ion⁴, but recent observations indicate the possibility of stereoselective syntheses of α - or 3-nucleosides starting from sugar derivatives with non-participating groups⁵.

In order to investigate the feasibility of this latter route, the use of a 2'-tosyl ribufuranose derivative appeared to be reasonable because tosyl group would be bulky enough to exercise complete stereochemical control during the glycosylation step.

Scheme I outlines the synthesis of the sugar moiety 3,5-di-0-(p-toluoyl)2-0-tosyl β -D-methyl ribofuranoside 5.

555



a) MeOH, H₂SO₄;
b) (iPr₂Si)₂O, pyridine; c) TsCl, DAMP;
d) Bu₄NF;
e) TolCl, pyridine

SCHEME I

For the synthesis of 5 we used 1,1,3,3-tetraisopropyl 1,3-dichlorodisilazane (TPDS-Cl₂) as a protecting group which allows the simultaneous 3,5-0protection of ribofuranosyl compounds⁶. Thus treatment of methyl β -D-ribofuranoside⁷ with the above mentioned reagent in the presence of pyridine gave the alcohol <u>2</u> in 66% yield⁸. Tosylation of the 2'-hydroxy function was effected with tosyl chloride in a solution of dimethylaminopyridine (DMAP) in acetonitrile. The ¹H NMR spectrum confirmed the position of the tosyl group since the H-2 resonance in <u>3</u> was observed to shift downfield by ca. 0.5 ppm from that observed in <u>2</u>. Compound <u>3</u> was deprotected by a solution of tetrabutylammonium fluoride in THF to give the diol <u>4</u> in 81% yield from <u>2</u>. This diol could be a versatile intermediate for synthetic studies since it is possible to distinguish between the primary and the secondary hydroxy functions⁹ (tritylation, benzoylation, acylation, silylation) or obtain 2-deoxyribose derivatives. Treatment of <u>4</u> with an excess of toluoyl chloride afforded the riboside 5 in 73% yield.

All the synthetic intermediates, as well as 5, were anomerically pure and their β -assignment was established by ¹H NMR¹⁰. The anomeric H-1 appears

as a singlet in complete agreement with the general trends observed in furanose glycosides¹¹.

Glycosylation of <u>5</u> (SCHEME II) with silylated uracil³ and adenine¹² in the presence of SnCl₄ led <u>exclusively</u> to the corresponding β -nucleosides: 3',5'-di-O-toluoyl 2'-tosyl uridine <u>6a</u> (H-1': 6.00 ppm J=3.6Hz) and 3',5'-di-O-toluoyl 2'-tosyl adenosine <u>6b</u> (H-1': 6.10 ppm J=5.0Hz) as shown by ¹H NMR analysis. Confirmation of the structure was obtained by hydrolysis (MeOH MeONa) to the known 2'-cyclouridine¹³ and 2'-tosyl adenosine⁶.



SCHEME II

In conclusion 2'-tosyl β -ribofuranoside 5 is an attractive compound for the direct synthesis of asymmetrically 2',3'-substituted β -ribonucleosides. Furthermore this approach represents a potentially general route to disymmetrically substituted oligoribonucleotide building blocks.

Acknowledgment: We thank the Swiss National Science Foundation for the support of these investigations.

REFERENCES

- 1) Nucleosides and Nucleotides part 23. For part 22 see reference 2.
- 2) Altermatt R., Tamm Ch., Helv. Chim. Acta 1985, 68, 475.
- 3) Niedballa V., Vorbrüggen H., J. Org. Chem. 1974, 39, 3654.
- Watanabe K.A., Hollenberg D.H., Fox J.J., J. Carbohydr. Nucleosides, Nucleotides <u>1974</u>, <u>1</u>, 1.
- 5) Chavis C., Dumont F., Wightman R.H., Ziegler J.C. Imbach J.L., J. Org. Chem. <u>1982</u>, <u>47</u>, 202. Kiss J., D'Souja R., J. Carbohydr. Nucleosides, Nucleotides <u>1980</u>, 7, 141. Michailov S.N., Pfleiderer W., Synthesis <u>1985</u>, 397.
- 6) Markiewcz W.T., J. Chem. Res. (M) 1979, 178.
- 7) Marker R., Fletcher H.G., J. Org. Chem. 1961, 26, 4605.
- 8) Robins M.J., Wilson J.S., Hansske F., J. Am. Chem. Soc. 1983, 105, 4059.

```
9) Hanessian S., Staub A.P., Tetrahedron Lett. 1973, 3555.
     Kim S., Chang H., Kim W.J., J. Org. Chem. 1985, 50, 1751.
     Posner G.H., Oda M., Tetrahedron Lett. 1981, 5003.
     Tanis S.P., Nakanishi K., J. Am. Chem. Soc. 1979, 101, 4398.
10) All the compounds gave HRMS and/or combustion analysis consistent with
     their structures.
     Selected physical data:
     Compound 2:
     [\alpha]_{D}^{25} = -37.1^{\circ} (c=3, CH_{2}Cl_{2})
     <sup>1</sup>H NMR (CDCl<sub>3</sub>): 4.81 (s, H-1); 4.51 (dd, H-3, J_{2,3}=J_{3,4}=5.3); 3.74-4.10
     (m, H-2, H-4, H-5, H-5'); 3.33 (s, -OCH<sub>3</sub>); 1.03-1.13 (m, i-Pr<sub>4</sub>)
     IR (CHCl<sub>2</sub>): 3550-3400 (-OH)
     Compound 3:
     [\alpha]_{D}^{25} = -16.1^{\circ} (c=4, CH_{2}Cl_{2})
     <sup>1</sup>H NMR (CDCl<sub>2</sub>): 7.80 (d, 2H, J=8.8); 7.29 (d, 2H, J=8.7)
     4.90 (s, H-1); 4.45-4.67 (m, H-2, H-3); 3.70-4.12 (m, H-4, H-5, H-5');
     3.33 (s, -OCH<sub>3</sub>); 2.43 (s, -CH<sub>3</sub>); 0.75-1.10 (m, i-Pr<sub>4</sub>)
     Compound 4:
     [\alpha]_{D}^{25} = -8.9^{\circ} (c=9, CHCl_{3})
     <sup>1</sup>H NMR (CDCl<sub>2</sub>); 7.75 (d, 2H, J=8.7); 7.37 (d, 2H, J=8.7); 4.83 (s, H-1);
     4.66 (d, H-2, J<sub>2,3</sub>=4.6); 4.20-4.50 (m, H-3, upon D<sub>2</sub>O addition: dd, J<sub>3.2</sub>=
     4.6, J<sub>3.4</sub>=5.7); 3.85-4.16 (m, H-4); 3.50-3.83 (m, H-5, H-5' upon D<sub>2</sub>O
     addition: dd, J<sub>4,5</sub>=4.0, J<sub>4,5</sub>,=4.5); 3.33 (s, -OCH<sub>3</sub>); 2.51 (d, -OH, J=6.7)
     2.50 (s, -CH<sub>3</sub>); 2.21 (m, -OH) 2.50 (s, -CH<sub>3</sub>); 2.21 (m, -OH)
     IR (CHCl<sub>2</sub>): 3600-3400 (-OH)
     Compound 5:
     [\alpha]_{D}^{25} = +39.5^{\circ} (c=4, CH<sub>3</sub>Cl); m.p. 98 C
     <sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.0-8.0 (m, 12H); 5.45 (dd, H-3, J_{3,2}=4.4, J_{3,4}=4.8); 5.10(s, H-1);
     5.03 (d, H-2, J_{2,3}=4.4); 4.25-4.73 (m, H-4, H-5, H-5'); 3.34 (s, -OCH_3);
     2.44 (s, -CH<sub>3</sub>); 2.38 (s, -CH<sub>3</sub>); 2.30 (s, -CH<sub>3</sub>)
     IR (CHCl<sub>3</sub>): 1720 (-CO)
11) Stevens J.D., Fletcher H.G., J. Org. Chem. 1968, 33, 1799.
12) Saneyoshi M., Satoh E., Chem. Pharm. Bull. 1979, 27, 2518.
13) Brown D.M., Todd A., Varadazajan S., J. Chem. Soc. 1956, 2389.
    (Received in Germany 13 November 1985)
```